Capecitabine Established as Standard of Care in Pre-Op Rectal Cancer Setting

Share this content:
Capecitabine should be considered a standard of care in the pre-operative rectal cancer setting.
Capecitabine should be considered a standard of care in the pre-operative rectal cancer setting.

Capecitabine should be considered a standard of care in the pre-operative rectal cancer setting, a recent study published online ahead of print in the Journal of the National Cancer Institute has shown.1

Researchers from various institutions across the United States designed the National Surgical Adjuvant Breast and Bowel Project R-04 to evaluate whether capecitabine, an oral fluoropyrimidine, could be substituted for continuous infusion fluorouracil (5-FU) for the treatment of patients with stage 2 or 3 rectal cancer with curative intent during neoadjuvant radiotherapy.

Researchers also sought to determine whether the addition of oxaliplatin could further improve the activity of fluoropyrimidine-sensitized radiation.

For the phase 3 trial, researchers enrolled 1,608 patients with clinical stage 2 or 3 rectal cancer undergoing preoperative radiotherapy. Participants were randomly assigned to receive continuous infusion 5-FU or capecitabine with or without oxaliplatin.

Results showed no statistically significant differences in 5-year disease-free survival, 3-year local-regional tumor event rates, or 5-year overall survival between regimens comparing 5-FU with capecitabine.

RELATED: Local Excision After CRT May Be Organ-Preserving Alternative for Rectal Cancer

Researchers also found no statistically significant differences between regimens with oxaliplatin and those without oxaliplatin. Oxaliplatin was significantly associated with increased overall and grade 3 to 4 diarrhea.

The findings suggest that oxaliplatin does not improve efficacy and increases toxicity in this patient population, and capecitabine combined with radiotherapy produces similar outcomes to those achieved with continuous infusion 5-FU.

Reference

  1. Allegra CJ, Yothers G, O'Connell MJ, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial [published online ahead of print September 14, 2015]. J Natl Cancer Inst. doi: 10.1093/jnci/djv248.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters